INDGN/SE/2026-27/37

30 July 2026

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001, India. Scrip Code: 544172	National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051, India. Trading symbol: INDGN

Dear Sir / Madam,

Subject: Press Release regarding financial results for the quarter ended June 30, 2026
Re: Regulation 30 read-with Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We wish to inform you that the Company has made a press release dated July 30, 2026, announcing the financial results for the quarter ended June 30, 2026 as approved by the Board of Directors at its meeting held on July 30, 2026. A copy of the Press Release is attached for your records.

This will also be posted on the company's website at: https://www.indegene.com/

We request you to kindly take the same on record.

Thanking You

Yours Sincerely,
For Indegene Limited

SRISHTI RAMESH KAUSHIK
Digitally signed by SRISHTI RAMESH KAUSHIK
Date: 2026.07.30 19:11:20 +05'30'

Srishti Ramesh Kaushik
Company Secretary and Compliance Officer

Encl: A/a

Press release

Indegene Delivers Strong Q1 FY27 Performance, Revenue Up 39.7% YoY

Strongest First-Quarter QoQ Revenue Growth in Four Years; PAT Up 45.9% QoQ

Bengaluru, India, July 30, 2026: Indegene, the strategic operating partner to the global life sciences industry, announced its financial results for the quarter ended June 30, 2026.

- **Revenue** of ₹10,631M ($112.5M), up **39.7 YoY** (**26.5% YoY** in $) & **6.0% QoQ**
- **EBITDA** ₹1,795M at **16.9%** margin, up **8.9% QoQ**, & **PAT** ₹1,162M at **10.9%** margin, up **45.9% QoQ**
- **Number of Active Clients** crossed the **100-milestone**, increasing by **14** sequentially to **105**
- Number of Customer in **$10M+ range** has expanded by **2** sequentially to **12**
- **Revenue per Employee (RPE)** further strengthened to **$77.1K** – the highest among peers

Sl. No.	Particulars	Quarter ended		
		Jun 30, 2026	Mar 31, 2026	Jun 30, 2025
1.	Revenue from operations	10,631	10,034	7,608
2.	Revenue from operations ($M)	112.5	109.7	88.9
3.	YoY revenue growth from operations (%)	39.7%	32.8%	12.5%
4.	EBITDA	1,795	1,648	1,536
5.	EBITDA margin (%)	16.9%	16.4%	20.2%
6.	Profit after tax	1,162	797	1,164
7.	Profit margin (%)	10.9%	7.9%	15.3%

"We started FY27 strongly, delivering sequential USD revenue growth of 2.5% - our strongest sequential growth in a first quarter in four years - and expanding our active client base to more than 100", said Manish Gupta, Chairman and CEO, Indegene. "We improved productivity, with revenue per employee rising to $77K - the highest in our peer group. We also deepened our client relationships, with 12 customers now generating more than $10 million in annual revenue each. We are focused on developing and scaling differentiated products, solutions and GenAI-powered technologies to advance AI-driven life sciences commercialization and drive the next phase of our growth."

"In Q1FY27, we delivered 39.7% YoY revenue growth in INR terms and 26.5% in USD. We expanded our active client base by 14 sequentially to 105. The increase in active clients reflects our investments in strengthening our sales and go-to-market teams last year", said Suhas Prabhu, CFO, Indegene. "Profitability improved in step with growth, with both EBITDA and PAT margins expanding sequentially. As these investments mature and ongoing engagements scale, we expect operating leverage to improve further and profitability to strengthen in the second half of the year."

About Indegene

Indegene Limited (BSE: 544172, NSE: INDGN) is the strategic operating partner to the global life sciences industry, orchestrating commercial, medical, R&D, and safety operations across the product lifecycle. Trusted by the world's top 20 biopharma companies, Indegene helps run complex, highly regulated workflows at global scale. Indegene combines deep life sciences expertise with AI-embedded platforms and governed operating models to improve speed, consistency, and compliance across mission-critical operations. By integrating technology into how work is executed and scaled, Indegene enables life sciences organizations to deliver measurable outcomes in regulated environments. For more information, visit www.indegene.com

For investor inquiries, please contact: IR@indegene.com
For media inquiries, please contact: yadunandan.kv@indegene.com